Table of Contents
- Executive Summary 5
- Strategic Considerations 5
- Stakeholder Implications 5
- Introduction 6
- What Market Awaits Innovative Therapies? 7
- Novel Approaches to Infl ammation/Autoimmune Disease Treatment 9
- Novel Targets 9
- MAP Kinases 9
- Jak 11
- Toll-Like Receptors 12
- Novel Interleukins 13
- Nuclear Factor-Kappa B 15
- Phosphodiesterase 4 15
- Novel Technologies 16
- RNA-Based Therapeutics 16
- Stem-Cell Therapy 17
- Company Profi les 18
- Archemix 18
- Array BioPharma 18
- Cellzome 18
- Dynavax 19
- Regulus Therapeutics 19
- Outlook 20
Tables
- 1. Descriptions of Infl ammatory and Autoimmune Diseases 6
- 2. Top-Selling Autoimmune and Anti-Infl ammatory Treatments, 2008
8
- 3. Common Immune Treatments and their Targets 10
- 4. MAP Kinase Agents in Clinical Development for Autoimmune and Infl
ammatory Diseases 11
- 5. Jak Kinase Agents in Development for Autoimmune and Infl ammatory
Diseases 12
- 6. Toll-Like Receptor Agents in Development for Autoimmune and Infl
ammatory Diseases 13
- 7. IL-12, IL-17, and IL-23 Agents in Development for Autoimmune and Infl
ammatory Diseases 14
- 8. NF-κB Agents in Development for Autoimmune and Infl ammatory
Diseases 15
- 9. PDE4 Agents in Development for Autoimmune and Infl ammatory Diseases
16
- 10. Select Deals in Autoimmune and Infl ammatory Disease Drug Development
21
- 11. Select Academic Collaborations in Autoimmune and Infl ammatory Disease
Drug Development 22
Figures
- 1. Worldwide Sales of Agents to Treat Infl ammatory and Autoimmune
Diseases, 2003-2008 7
- 2. Market Share of the Autoimmune and Infl ammatory Disease Market by
Company, 2008 8
|
Related Report
|
View Cart
